{"log_id": 4487714239713902963, "direction": 0, "words_result_num": 31, "words_result": [{"probability": {"variance": 3e-06, "average": 0.998991, "min": 0.99174}, "location": {"width": 825, "top": 162, "height": 51, "left": 238}, "words": "联合使用不会导致非预期的安全性事件,且本品与甲氨蝶呤联合使用的安全性特"}, {"probability": {"variance": 8.5e-05, "average": 0.996712, "min": 0.954587}, "location": {"width": 820, "top": 212, "height": 50, "left": 240}, "words": "点与本品或甲氨蝶呤单独使用时报告的安全性特点相似。目前正在进行长期联合"}, {"probability": {"variance": 1.8e-05, "average": 0.998627, "min": 0.975588}, "location": {"width": 824, "top": 259, "height": 51, "left": 236}, "words": "用药安全性特点的评估。本品与其他改善病情的抗风湿药物( DMARD)共同使"}, {"probability": {"variance": 0, "average": 0.999384, "min": 0.997468}, "location": {"width": 362, "top": 306, "height": 40, "left": 234}, "words": "用时,恩利的长期安全性还未确定"}, {"probability": {"variance": 2e-06, "average": 0.998975, "min": 0.993572}, "location": {"width": 669, "top": 355, "height": 49, "left": 280}, "words": "尚未进行本品与银屑病的其他系统疗法或光疗法共同使用的研究"}, {"probability": {"variance": 0, "average": 0.999326, "min": 0.997897}, "location": {"width": 174, "top": 403, "height": 35, "left": 230}, "words": "肾和肝功能损害"}, {"probability": {"variance": 1e-06, "average": 0.99931, "min": 0.997099}, "location": {"width": 777, "top": 452, "height": 52, "left": 277}, "words": "根据药代动力学资料(参见“药代动力学”),肝或肾功能损害患者无需进"}, {"probability": {"variance": 2.1e-05, "average": 0.998347, "min": 0.978877}, "location": {"width": 458, "top": 500, "height": 41, "left": 227}, "words": "行剂量调整;针对这些患者的临床经验有限"}, {"probability": {"variance": 3e-06, "average": 0.998618, "min": 0.994685}, "location": {"width": 173, "top": 547, "height": 35, "left": 225}, "words": "充血性心力衰竭"}, {"probability": {"variance": 0.008044, "average": 0.961593, "min": 0.556862}, "location": {"width": 778, "top": 597, "height": 46, "left": 272}, "words": "充血性心力衰竭(CHF)患者使用本品时,医师应特别值上市后曾有使"}, {"probability": {"variance": 0.005375, "average": 0.983326, "min": 0.567269}, "location": {"width": 811, "top": 639, "height": 56, "left": 223}, "words": "用本品的患者在有或无明显促发因素的情况下出现充血性心方衰竭加重的报告"}, {"probability": {"variance": 0.000244, "average": 0.994021, "min": 0.920005}, "location": {"width": 825, "top": 688, "height": 55, "left": 220}, "words": "两项用于评价本品治疗充血性心力衰竭患者的大规模临床试验因缺乏疗效而终"}, {"probability": {"variance": 0.008083, "average": 0.974334, "min": 0.515952}, "location": {"width": 826, "top": 732, "height": 62, "left": 220}, "words": "止。尽管不是最终结论,但其中一项试验的资科显示使用本品治疗的患者可能荐"}, {"probability": {"variance": 1e-06, "average": 0.999079, "min": 0.997012}, "location": {"width": 314, "top": 785, "height": 38, "left": 219}, "words": "在加重充血性心力衰竭的倾向"}, {"probability": {"variance": 0, "average": 0.99929, "min": 0.998057}, "location": {"width": 124, "top": 835, "height": 28, "left": 217}, "words": "酒精性肝炎"}, {"probability": {"variance": 0.048922, "average": 0.685339, "min": 0.464155}, "location": {"width": 115, "top": 748, "height": 129, "left": 899}, "words": "兰吧"}, {"probability": {"variance": 0, "average": 0.981448, "min": 0.981448}, "location": {"width": 151, "top": 828, "height": 74, "left": 974}, "words": "★"}, {"probability": {"variance": 0.000902, "average": 0.991066, "min": 0.834375}, "location": {"width": 851, "top": 877, "height": 57, "left": 263}, "words": "在一项Ⅱ期随机安慰剂对照的研究中,对48例患有中度或重度酒精性肝炎"}, {"probability": {"variance": 0.025879, "average": 0.928065, "min": 0.356285}, "location": {"width": 906, "top": 896, "height": 91, "left": 210}, "words": "的住院病人进行本品或安慰剂治价结果显示,本品治疗无效,并且治疗名"}, {"probability": {"variance": 0.006002, "average": 0.981464, "min": 0.535768}, "location": {"width": 813, "top": 973, "height": 55, "left": 210}, "words": "后,本品用药组的死亡率明显较高。所以,不推荐酒精性肝炎病人使用本品治疗"}, {"probability": {"variance": 8.3e-05, "average": 0.995505, "min": 0.95227}, "location": {"width": 767, "top": 1017, "height": 63, "left": 209}, "words": "对于患有中度或重度酒精性肝炎的患者使用本品治疗时,医生应谨慎使用"}, {"probability": {"variance": 0.010569, "average": 0.906233, "min": 0.707754}, "location": {"width": 198, "top": 1070, "height": 39, "left": 212}, "words": " Wegener I氏肉芽肿"}, {"probability": {"variance": 0.000399, "average": 0.993777, "min": 0.910459}, "location": {"width": 779, "top": 1117, "height": 54, "left": 255}, "words": "在一项平均持续时间为25个月安慰剂对照试验中,89名成年患者接受本品"}, {"probability": {"variance": 4e-06, "average": 0.998181, "min": 0.991346}, "location": {"width": 827, "top": 1165, "height": 52, "left": 204}, "words": "和标准疗法(包括环磷酰胺、甲氨蝶呤和糖皮质激素),结果并未显示本品对"}, {"probability": {"variance": 3.8e-05, "average": 0.997488, "min": 0.970581}, "location": {"width": 825, "top": 1214, "height": 50, "left": 205}, "words": " Wegener氏肉芽肿的治疗有效。本品治疗组出现各种类型非皮肤恶性肿瘤的发生"}, {"probability": {"variance": 1.9e-05, "average": 0.997242, "min": 0.980422}, "location": {"width": 624, "top": 1260, "height": 48, "left": 202}, "words": "率显著高于对照组。不推荐使用本品治疗 Wegener氏肉芽肿"}, {"probability": {"variance": 1e-06, "average": 0.999495, "min": 0.996172}, "location": {"width": 270, "top": 1301, "height": 37, "left": 201}, "words": "治疗糖尿病患者的低血糖"}, {"probability": {"variance": 1e-06, "average": 0.999449, "min": 0.99698}, "location": {"width": 777, "top": 1357, "height": 51, "left": 248}, "words": "有报告对于接受糖尿病治疗的患者,开始使用本品后会伴有低血糖,需要对"}, {"probability": {"variance": 3e-06, "average": 0.998913, "min": 0.993737}, "location": {"width": 363, "top": 1405, "height": 39, "left": 223}, "words": "些患者减少治疗糖尿病药物的使用"}, {"probability": {"variance": 1e-06, "average": 0.999093, "min": 0.997558}, "location": {"width": 279, "top": 1452, "height": 37, "left": 203}, "words": "【孕妇及哺乳期妇女用药】"}, {"probability": {"variance": 2e-06, "average": 0.998863, "min": 0.992256}, "location": {"width": 779, "top": 1502, "height": 49, "left": 243}, "words": "没有开展妊娠妇女使用本品的研究,因此尚未建立妊娠妇女使用本品的安全"}], "language": 3}